Evoke Pharma Inc. (EVOK) Trading Down 2.8%
Evoke Pharma Inc. (NASDAQ:EVOK)’s share price fell 2.8% on Tuesday . The stock traded as low as $2.07 and last traded at $2.07, with a volume of 318,503 shares. The stock had previously closed at $2.13.
Several brokerages have recently weighed in on EVOK. FBR & Co reiterated a “buy” rating on shares of Evoke Pharma in a research note on Saturday, May 14th. Zacks Investment Research cut shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, May 5th. Brean Capital restated a “buy” rating on shares of Evoke Pharma in a research note on Thursday, May 12th. Rodman & Renshaw restated a “buy” rating on shares of Evoke Pharma in a research note on Thursday, May 12th. Finally, Noble Financial cut shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, July 19th. One analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company. Evoke Pharma has a consensus rating of “Hold” and an average price target of $10.28.
The company’s market cap is $25.56 million. The stock’s 50 day moving average is $3.96 and its 200-day moving average is $4.66.
Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings results on Monday, August 15th. The specialty pharmaceutical company reported ($0.41) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.02. On average, equities analysts expect that Evoke Pharma Inc. will post ($1.25) EPS for the current year.
In other news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the business’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $4.70, for a total transaction of $1,617,364.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.